ArticleBritish journal of cancer2021
Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.
Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Proton pump inhibitors associated with an increased risk of mortality in elderly: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials.Scientific reports · 2024Trial
- The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors.Nature reviews. Cancer · 2026Review
- Proton pump inhibitors and all-cause mortality in colorectal cancer.Scientific reports · 2025Article
- Proton pump inhibitors and all-cause mortality risk among cancer patients.World journal of clinical oncology · 2025Article
- Increased risk of adenomatous colon polyps in patients with long-term use of proton pump inhibitors: a single-center retrospective study.Journal of Yeungnam medical science · 2025Article
- Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.Digestive diseases and sciences · 2023Article
- Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.Chonnam medical journal · 2023Review
- Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.ESMO open · 2023Review
- Influence of proton pump inhibitors on the pathological response of rectal cancer: a multicentre study.Ecancermedicalscience · 2023Article
- Review
- Re-thinking the possible interaction between proton pump inhibitors and capecitabine.Cancer chemotherapy and pharmacology · 2022Review
- Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality.Gastroenterology · 2022Article
- Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProton pump inhibitors (PPIs) are associated with microbiome changes of the gut, which in turn may affect the progression of colorectal cancer (CRC). This study aims to assess the associations between PPI use and all-cause and CRC-specific mortality.
methodsWe selected all patients registered in the Swedish Prescribed Drug Registry who were diagnosed with CRC between 2006 and 2012 (N = 32,411, 54.9% PPI users) and subsequently followed them through register linkage to the Swedish Causes of Death Registry until December 2013. PPI users were patients with ≥1 post-diagnosis PPI dispensation. Time-dependent Cox-regression models were performed with PPI use as time-varying exposure.
resultsOverall 4746 (14.0%) patients died, with an aHR of 1.38 (95% CI 1.32-1.44) for all-cause mortality comparing PPI users with PPI nonusers. Higher-magnitude associations were observed among male, cancer stage 0-I, rectal cancer and patients receiving CRC surgery. The PPI-all-cause mortality association was also more pronounced comparing new users to non-users (aHR = 1.47, 95%CI 1.40-1.55) than comparing continuous users to non-users (aHR = 1.32, 95%CI 1.24-1.39). The risk estimates for CRC-specific mortality comparing PPI users to PPI nonusers were similar to those for all-cause mortality.
conclusionPPI use after the CRC diagnosis was associated with increased all-cause and CRC-specific mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.